UroGen Pharma (UroGen Pharma) Float Percentage Of Total Shares Outstanding : 92.41% (As of Apr. 30, 2024)

View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, UroGen Pharma's float shares is 31.53 Mil. UroGen Pharma's total shares outstanding is 34.12 Mil. UroGen Pharma's float percentage of total shares outstanding is 92.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, UroGen Pharma's Insider Ownership is 2.97%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, UroGen Pharma's Institutional Ownership is 14.43%.

UroGen Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

UroGen Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	31.53	/	34.12
	=	92.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma (UroGen Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

UR8:Germany UR8:Germany

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Executives

Jason Drew Smith	officer: General Counsel	C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Mark Schoenberg	officer: Chief Medical Officer	C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Daniel George Wildman	director	12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen	director	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim	officer: Chief Financial Officer	C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett	officer: Chief Executive Officer	C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix	officer: COO	C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden	director	C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur	director, officer: Chief Executive Officer	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen	director	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102